Related Experiment Video

Updated: Feb 15, 2026

Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue
06:36

Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue

Published on: May 1, 2019

7.5K

[Progress of treatment of new targets in gastric cancer]

M Zhuo1, T Han1, X Y Xiao1

  • 1Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China.

Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery
|February 13, 2026
PubMed

Insights

Biomarkers like HER-2 and Claudin 18.2 (CLDN 18.2) are revolutionizing advanced gastric cancer treatment. Ongoing research into new targets promises improved patient outcomes through personalized therapies.

Area of Science:

  • Oncology
  • Precision Medicine
  • Molecular Diagnostics

Background:

  • Biomarkers such as HER-2, PD-L1, and Claudin 18.2 (CLDN 18.2) are crucial for advancing precision treatment in oncology.
  • HER-2 targeted therapies show advancements, while immune checkpoint inhibitors offer survival benefits to a subset of patients.
  • Claudin 18.2 (CLDN 18.2) is an emerging target with demonstrated potential in advanced gastric cancer treatment.

Purpose of the Study:

  • To review the role of established and emerging biomarkers in precision treatment for advanced gastric cancer.
  • To highlight the therapeutic advancements and ongoing research for targets like HER-2, PD-L1, CLDN 18.2, FGFR2b, MET, DKK1, and TROP2.
  • To underscore the potential of biomarker-driven strategies to improve prognosis in advanced gastric cancer.

Main Methods:

  • Literature review of clinical studies and research on biomarkers for gastric cancer.
  • Analysis of therapeutic advancements and limitations associated with current biomarkers.
  • Exploration of ongoing research into novel molecular targets for personalized treatment.

Main Results:

  • HER-2 targeted therapies have advanced significantly.
  • Immune checkpoint inhibitors provide survival benefits for a portion of patients.
  • Claudin 18.2 (CLDN 18.2) targeted therapies, including Zolbetuximab, are approved and offer new treatment avenues.
  • Research continues on targets like FGFR2b, MET, DKK1, and TROP2 for personalized gastric cancer treatment.

Conclusions:

  • Current biomarkers have limitations, but continuous discovery of new targets is promising.
  • Precision treatment strategies based on biomarkers hold significant potential for improving advanced gastric cancer prognosis.
  • Further clinical research is essential to fully realize the benefits of personalized medicine in gastric cancer.

More Related Videos

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines08:42

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines

Published on: July 19, 2019

10.8K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Gastric Motility01:16

Gastric Motility

Gastric motility is the coordinated contraction and relaxation of stomach muscles that convert ingested food into chyme, a semi-liquid substance ready for further digestion in the intestines. The process begins with the vagus nerve inducing the relaxation of the smooth muscles in the fundus and body of the stomach, allowing these regions to expand and accommodate up to approximately 1.5 liters of food and liquid.
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
3.3K
Gastric Emptying01:16

Gastric Emptying

Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
4.0K
Gastric Phase of Digestion01:26

Gastric Phase of Digestion

The gastric phase of digestion begins as soon as food enters the stomach. The incoming food bolus triggers neural and hormonal mechanisms, which last approximately 3 to 4 hours. During this phase, the stomach undergoes significant changes to prepare the food for further digestion and absorption.
When food enters the stomach, it stretches the stomach walls and activates stretch receptors. This triggers local reflexes of the enteric nervous system, mediated through the myenteric plexus. These...
3.6K